COL22A1: A Promising Drug Target / Biomarker (G169044)

Target Name: COL22A1

NCBI ID: G169044

COL22A1

Other Name(s): collagen type XXII alpha 1 chain | Collagen alpha-1(XXII) chain | Collagen type XXII alpha 1 chain | Alpha 1 type XXII collagen (COL22A1) | COMA1_HUMAN

COL22A1: A Promising Drug Target / Biomarker

COL22A1 is a protein that is expressed in human tissues and has been identified as a potential drug target or biomarker. The protein is a member of the tight junction protein family and is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is also expressed in the placenta and has been shown to play a role in the development and progression of various diseases, including cancer.

The discovery of COL22A1 as a potential drug target or biomarker has significant implications for the treatment of these diseases. Currently, there are no approved drugs that target COL22A1, and research is being conducted to understand its potential utility as a drug target or biomarker.

Expression and Localization of COL22A1

COL22A1 is a transmembrane protein that is expressed in various tissues throughout the body. It is primarily expressed in the lungs, where it is involved in the regulation of cell signaling and fibrosis. The protein is also expressed in the heart, kidneys, and intestines, where it is involved in the regulation of blood pressure and the production of hormones.

COL22A1 is expressed in the placenta, where it has been shown to play a role in the development and progression of various diseases, including cancer. Studies have shown that high levels of COL22A1 expression are associated with an increased risk of cancer, and that inhibiting the function of the protein may be a promising strategy for cancer treatment.

Drug Interactions withCOL22A1

There is currently no evidence that COL22A1 is a drug target or biomarker that is widely recognized by the scientific community. However, studies have shown that the protein is involved in several cellular signaling pathways, including the TGF-β pathway and the Wnt pathway. These pathways are involved in cell growth, differentiation, and survival, and have been implicated in a variety of diseases, including cancer.

Colorado Research Institute (CRI)

The Colorado Research Institute (CRI) is a non-profit research organization that is focused on the discovery and development of new treatments for cancer. The CRI has conducted research on COL22A1 and has identified the protein as a potential drug target or biomarker. The CRI is currently conducting research to understand the function of COL22A1 and to identify potential small molecules that can inhibit its activity.

The CRI has also established a collaboration with the National Cancer Institute (NCI) to further their research on COL22A1 and its potential as a drug target or biomarker. The NCI is providing funding and resources to support the CRI's research and is also involved in the analysis of data from the CRI's studies.

Conclusion

COL22A1 is a protein that is expressed in various tissues throughout the body and has been identified as a potential drug target or biomarker. The protein is a member of the tight junction protein family and has been shown to play a role in the development and progression of various diseases, including cancer. While there is currently no approved drug that targets COL22A1, research is being conducted to understand its potential utility as a drug target or biomarker. The Colorado Research Institute and the National Cancer Institute are collaborating to further their research on the protein and to identify potential small molecules that can inhibit its activity.

Protein Name: Collagen Type XXII Alpha 1 Chain

Functions: Acts as a cell adhesion ligand for skin epithelial cells and fibroblasts

The "COL22A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COL22A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets